Amgen Reports Positive VESALIUS-CV Trial Results for Repatha
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: NASDAQ.COM
- Clinical Trial Results: Amgen's analysis of 6,002 patients in the VESALIUS-CV trial revealed that Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% in patients receiving statins or LDL-C-lowering therapies, demonstrating its efficacy in high-risk populations.
- LDL-C Reduction Effectiveness: The median LDL-C level in the Repatha group was 45 mg/dL compared to 106 mg/dL in the placebo group, indicating a significant advantage of Repatha in lowering LDL-C levels, which may provide new treatment options for cardiovascular disease prevention.
- Market Performance: Amgen's stock has traded between $267.83 and $391.29 over the past year, closing at $349.58, up 1.15% from the previous trading day, reflecting positive market sentiment towards its new drug development results.
- Future Outlook: With the FDA expanding Repatha's indications, Amgen is poised to further increase its market share, particularly among high-risk diabetes patients, enhancing its competitive position in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 344.565
Low
280.00
Averages
363.10
High
425.00
Current: 344.565
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amgen Rated Among Most Profitable Dividend Stocks
- Strong Profitability: Amgen Inc. (NASDAQ:AMGN) boasts a net profit margin of 20.96%, earning a spot among the 10 most profitable dividend stocks to invest in now, highlighting its robust performance and stable cash flow in the biotechnology sector.
- Rating Adjustment: Goldman Sachs lowered its price target for Amgen from $425 to $389 while maintaining a Buy rating, indicating confidence in the company's long-term growth potential despite facing an IRS audit dispute.
- Revenue Growth Outlook: Piper Sandler reduced its price target for Amgen from $432 to $427; however, the firm remains optimistic about revenue growth in 2026 and 2027, driven primarily by continued momentum in its rare disease business, particularly Uplizna.
- Market Competition Analysis: While Amgen is viewed as a promising investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, prompting investors to consider more attractive investment opportunities.
See More
Amgen Reports Positive VESALIUS-CV Trial Results for Repatha
- Clinical Trial Results: Amgen's analysis of 6,002 patients in the VESALIUS-CV trial revealed that Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% in patients receiving statins or LDL-C-lowering therapies, demonstrating its efficacy in high-risk populations.
- LDL-C Reduction Effectiveness: The median LDL-C level in the Repatha group was 45 mg/dL compared to 106 mg/dL in the placebo group, indicating a significant advantage of Repatha in lowering LDL-C levels, which may provide new treatment options for cardiovascular disease prevention.
- Market Performance: Amgen's stock has traded between $267.83 and $391.29 over the past year, closing at $349.58, up 1.15% from the previous trading day, reflecting positive market sentiment towards its new drug development results.
- Future Outlook: With the FDA expanding Repatha's indications, Amgen is poised to further increase its market share, particularly among high-risk diabetes patients, enhancing its competitive position in the biopharmaceutical sector.
See More
Repatha Significantly Reduces Cardiovascular Event Risk in High-Risk Diabetes Patients
- Cardiovascular Event Risk Reduction: In patients with high-risk diabetes, the combination of Repatha® with statins reduced the risk of cardiovascular events by 29%, highlighting its critical role in cardiovascular disease prevention and potentially driving increased market demand.
- Significant LDL-C Reduction: The median LDL-C level in the Repatha group was 45 mg/dL compared to 106 mg/dL in the placebo group, demonstrating the drug's effectiveness in lowering 'bad' cholesterol, which may enhance physician confidence in prescribing it.
- Adherence Issues: Despite the effectiveness of GLP-1 therapies in improving glycemic control and weight, studies show low treatment adherence within the first year, underscoring the need for new strategies to improve long-term patient outcomes.
- Clinical Trial Results Presentation: Results from the VESALIUS-CV trial were presented at the American Diabetes Association meeting, further validating the clinical benefits of Repatha in high-risk diabetes patients, which may strengthen its market position in cardiovascular disease treatment.
See More
Repatha® Reduces Major Cardiovascular Events by 29% in High-Risk Diabetes Patients
- Cardiovascular Risk Reduction: The VESALIUS-CV study involving 6,002 high-risk diabetes patients demonstrated that Repatha® reduced the risk of major cardiovascular events by 29% compared to placebo, highlighting its critical role in heart disease prevention.
- Significant LDL-C Reduction: The median LDL-C level in the Repatha® group was 45 mg/dL, compared to 106 mg/dL in the placebo group, indicating the drug's effectiveness in lowering 'bad' cholesterol, which is vital for improving cardiovascular health.
- Adherence Issues: Despite the effectiveness of GLP-1 therapies in improving glycemic control and weight, studies reveal low adherence rates in routine clinical practice, with many patients discontinuing treatment within the first year, potentially limiting the realization of treatment benefits.
- Need for Long-Term Treatment: Amgen emphasizes the necessity of sustained long-term treatment to achieve the full therapeutic benefits for chronic conditions like diabetes and obesity, advocating for the development of new treatment strategies to enhance patient adherence.
See More
Repatha® Significantly Reduces Cardiovascular Event Risk in High-Risk Diabetes Patients
- Cardiovascular Risk Reduction: In patients with high-risk diabetes, Repatha® demonstrated a 29% reduction in the risk of major cardiovascular events when used alongside statins, highlighting its critical role in preventing cardiovascular diseases, particularly in those without prior heart attacks or strokes.
- Significant LDL-C Reduction: The median LDL-C level in the Repatha group was 45 mg/dL compared to 106 mg/dL in the placebo group, indicating Repatha's effectiveness in lowering 'bad' cholesterol, which is vital for improving overall cardiovascular health in patients.
- Adherence Issues: Despite the effectiveness of GLP-1 therapies in improving glycemic control and weight, studies reveal low adherence rates in routine clinical practice, with many patients discontinuing treatment within the first year, potentially limiting the realization of treatment benefits and underscoring the need for new strategies.
- Need for Long-Term Treatment: Amgen's research emphasizes the importance of sustained treatment to achieve optimal outcomes for chronic conditions like diabetes and obesity, indicating a pressing need for innovative treatment approaches in managing cardiovascular and metabolic diseases.
See More
Recommended High-Yield ETF: Schwab U.S. Dividend Equity ETF
- Income and Growth Balance: The Schwab U.S. Dividend Equity ETF boasts a dividend yield of 3.25% and has risen 19% year-to-date in 2026, delivering slightly lower growth than the S&P 500 while providing nearly three times the dividend income, indicating a strong balance between income and growth.
- Expense Ratio Advantage: With an expense ratio of just 0.06%, investors pay only $6 for every $10,000 invested, making it competitive among similar products and enhancing net returns for investors.
- Robust Portfolio Composition: The ETF tracks the Dow Jones U.S. Dividend 100 Index, comprising 100 stocks with a history of at least 10 years of dividend payments, ensuring financial health among constituents and reducing the risk of dividend cuts due to financial troubles, thus enhancing long-term investment safety.
- Diversified Holdings Structure: The top ten holdings account for about 43% of the ETF, with 18% in consumer defensive stocks, 15% in energy, and 18% in healthcare, providing a diversified allocation that helps maintain stability and risk resistance in the event of a market pullback.
See More
Amgen Rated Among Most Profitable Dividend Stocks
- Strong Profitability: Amgen Inc. (NASDAQ:AMGN) boasts a net profit margin of 20.96%, earning a spot among the 10 most profitable dividend stocks to invest in now, highlighting its robust performance and stable cash flow in the biotechnology sector.
- Rating Adjustment: Goldman Sachs lowered its price target for Amgen from $425 to $389 while maintaining a Buy rating, indicating confidence in the company's long-term growth potential despite facing an IRS audit dispute.
- Revenue Growth Outlook: Piper Sandler reduced its price target for Amgen from $432 to $427; however, the firm remains optimistic about revenue growth in 2026 and 2027, driven primarily by continued momentum in its rare disease business, particularly Uplizna.
- Market Competition Analysis: While Amgen is viewed as a promising investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, prompting investors to consider more attractive investment opportunities.
See More
Amgen Reports Positive VESALIUS-CV Trial Results for Repatha
- Clinical Trial Results: Amgen's analysis of 6,002 patients in the VESALIUS-CV trial revealed that Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 29% in patients receiving statins or LDL-C-lowering therapies, demonstrating its efficacy in high-risk populations.
- LDL-C Reduction Effectiveness: The median LDL-C level in the Repatha group was 45 mg/dL compared to 106 mg/dL in the placebo group, indicating a significant advantage of Repatha in lowering LDL-C levels, which may provide new treatment options for cardiovascular disease prevention.
- Market Performance: Amgen's stock has traded between $267.83 and $391.29 over the past year, closing at $349.58, up 1.15% from the previous trading day, reflecting positive market sentiment towards its new drug development results.
- Future Outlook: With the FDA expanding Repatha's indications, Amgen is poised to further increase its market share, particularly among high-risk diabetes patients, enhancing its competitive position in the biopharmaceutical sector.
See More
Repatha Significantly Reduces Cardiovascular Event Risk in High-Risk Diabetes Patients
- Cardiovascular Event Risk Reduction: In patients with high-risk diabetes, the combination of Repatha® with statins reduced the risk of cardiovascular events by 29%, highlighting its critical role in cardiovascular disease prevention and potentially driving increased market demand.
- Significant LDL-C Reduction: The median LDL-C level in the Repatha group was 45 mg/dL compared to 106 mg/dL in the placebo group, demonstrating the drug's effectiveness in lowering 'bad' cholesterol, which may enhance physician confidence in prescribing it.
- Adherence Issues: Despite the effectiveness of GLP-1 therapies in improving glycemic control and weight, studies show low treatment adherence within the first year, underscoring the need for new strategies to improve long-term patient outcomes.
- Clinical Trial Results Presentation: Results from the VESALIUS-CV trial were presented at the American Diabetes Association meeting, further validating the clinical benefits of Repatha in high-risk diabetes patients, which may strengthen its market position in cardiovascular disease treatment.
See More
Repatha® Reduces Major Cardiovascular Events by 29% in High-Risk Diabetes Patients
- Cardiovascular Risk Reduction: The VESALIUS-CV study involving 6,002 high-risk diabetes patients demonstrated that Repatha® reduced the risk of major cardiovascular events by 29% compared to placebo, highlighting its critical role in heart disease prevention.
- Significant LDL-C Reduction: The median LDL-C level in the Repatha® group was 45 mg/dL, compared to 106 mg/dL in the placebo group, indicating the drug's effectiveness in lowering 'bad' cholesterol, which is vital for improving cardiovascular health.
- Adherence Issues: Despite the effectiveness of GLP-1 therapies in improving glycemic control and weight, studies reveal low adherence rates in routine clinical practice, with many patients discontinuing treatment within the first year, potentially limiting the realization of treatment benefits.
- Need for Long-Term Treatment: Amgen emphasizes the necessity of sustained long-term treatment to achieve the full therapeutic benefits for chronic conditions like diabetes and obesity, advocating for the development of new treatment strategies to enhance patient adherence.
See More
Repatha® Significantly Reduces Cardiovascular Event Risk in High-Risk Diabetes Patients
- Cardiovascular Risk Reduction: In patients with high-risk diabetes, Repatha® demonstrated a 29% reduction in the risk of major cardiovascular events when used alongside statins, highlighting its critical role in preventing cardiovascular diseases, particularly in those without prior heart attacks or strokes.
- Significant LDL-C Reduction: The median LDL-C level in the Repatha group was 45 mg/dL compared to 106 mg/dL in the placebo group, indicating Repatha's effectiveness in lowering 'bad' cholesterol, which is vital for improving overall cardiovascular health in patients.
- Adherence Issues: Despite the effectiveness of GLP-1 therapies in improving glycemic control and weight, studies reveal low adherence rates in routine clinical practice, with many patients discontinuing treatment within the first year, potentially limiting the realization of treatment benefits and underscoring the need for new strategies.
- Need for Long-Term Treatment: Amgen's research emphasizes the importance of sustained treatment to achieve optimal outcomes for chronic conditions like diabetes and obesity, indicating a pressing need for innovative treatment approaches in managing cardiovascular and metabolic diseases.
See More
Recommended High-Yield ETF: Schwab U.S. Dividend Equity ETF
- Income and Growth Balance: The Schwab U.S. Dividend Equity ETF boasts a dividend yield of 3.25% and has risen 19% year-to-date in 2026, delivering slightly lower growth than the S&P 500 while providing nearly three times the dividend income, indicating a strong balance between income and growth.
- Expense Ratio Advantage: With an expense ratio of just 0.06%, investors pay only $6 for every $10,000 invested, making it competitive among similar products and enhancing net returns for investors.
- Robust Portfolio Composition: The ETF tracks the Dow Jones U.S. Dividend 100 Index, comprising 100 stocks with a history of at least 10 years of dividend payments, ensuring financial health among constituents and reducing the risk of dividend cuts due to financial troubles, thus enhancing long-term investment safety.
- Diversified Holdings Structure: The top ten holdings account for about 43% of the ETF, with 18% in consumer defensive stocks, 15% in energy, and 18% in healthcare, providing a diversified allocation that helps maintain stability and risk resistance in the event of a market pullback.
See More
